07:00 , Mar 11, 2013 |  BioCentury  |  Regulation

Dissecting Kadcyla

Two and a half years after FDA refused to file Genentech Inc. 's BLA for accelerated approval of Kadcyla ado-trastuzumab emtansine in metastatic breast cancer, the agency has granted full approval - and outlined its...
08:00 , Jan 14, 2013 |  BC Week In Review  |  Clinical News

Eniluracil: Completed Phase II enrollment

Adherex completed enrollment of 153 patients in the open-label, international Phase II AHX-03-202 trial comparing 40 mg oral eniluracil weekly for the first 3 weeks of a 4-week cycle plus oral 5-fluorouracil (5-FU) and oral...
08:00 , Dec 17, 2012 |  BC Week In Review  |  Clinical News

Eniluracil: Interim Phase II data

Interim data from 122 evaluable patients who had previously been treated with an anthracycline and taxane in the open-label, international Phase II AHX-03-202 trial showed that once-weekly 40 mg oral eniluracil for the first 3...
07:00 , Apr 11, 2011 |  BC Week In Review  |  Clinical News

Eniluracil: Phase II started

Adherex began the open-label, international Phase II (AHX-03-202) trial in about 140 patients to compare 40 mg oral eniluracil weekly for the first 3 weeks of a 4-week cycle plus 5-fluorouracil (5-FU) and leucovorin vs....
07:00 , Jul 13, 2009 |  BC Week In Review  |  Company News

Adherex cancer news

Adherex reshuffled its management and said it will focus its remaining resources on the development of eniluracil , after restructuring and reducing headcount in April. Adherex hired shareholder Rosty Raykov as CEO and a director...
08:00 , Nov 24, 2008 |  BC Week In Review  |  Clinical News

Eniluracil: Phase I/II suspended enrollment

Adherex closed enrollment in a dose-escalation, Asian Phase I/II trial after a reprioritization of its development programs. The trial, which had enrolled 9 patients, is evaluating oral eniluracil in combination with 5-fluorouracil. Adherex has exclusive...
08:00 , Nov 24, 2008 |  BC Week In Review  |  Clinical News

Eniluracil: Phase I suspended enrollment

Adherex said it has temporarily suspended enrollment in a U.S. Phase I trial after a reprioritization of its development programs. The trial, which has enrolled 41 patients, is evaluating oral eniluracil in combination with 5-fluorouracil....
08:00 , Nov 17, 2008 |  BC Week In Review  |  Company News

Adherex cancer news

Adherex will rationalize its clinical programs to conserve cash. The company will focus on its Phase III trials of sodium thiosulfate (STS) to treat liver cancer and to prevent hearing loss in children receiving cisplatin-based...
08:00 , Mar 5, 2007 |  BC Week In Review  |  Company News

Adherex, GlaxoSmithKline deal

AHX completed its previously announced acquisition of GSK's buy-back option to eniluracil for $1 million (see BioCentury, Jan. 22). Adherex Technologies Inc. (TSX:AHX; ADH), Durham, N.C.   GlaxoSmithKline plc (LSE:GSK; GSK), London, U.K.   Business:...
08:00 , Jan 22, 2007 |  BC Week In Review  |  Company News

Adherex, GlaxoSmithKline deal

AHX will pay GSK $1 million to acquire the pharma company's buy-back option to eniluracil . AHX licensed rights to the oral dihydropyrimidine dehydrogenase (DPD) inhibitor from GSK in 2005 (see BioCentury, July 18, 2005)....